Published in Am J Pathol on December 18, 2008
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb Perspect Biol (2012) 1.18
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol (2009) 1.05
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone (2013) 0.94
Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res (2015) 0.90
Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem Biophys Res Commun (2011) 0.90
Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporos Int (2010) 0.89
Efavirenz is associated with higher bone mass in South African children with HIV. AIDS (2016) 0.82
Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease. AIDS (2016) 0.79
The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS (2016) 0.78
Activation and function of small GTPases Rho, Rac, and Cdc42 during gastrulation. Methods Mol Biol (2012) 0.78
HIV-1 protein induced modulation of primary human osteoblast differentiation and function via a Wnt/β-catenin-dependent mechanism. J Orthop Res (2012) 0.78
Polygonatum sibiricum polysaccharide inhibits osteoporosis by promoting osteoblast formation and blocking osteoclastogenesis through Wnt/β-catenin signalling pathway. Sci Rep (2016) 0.77
Id transcriptional regulators in adipogenesis and adipose tissue metabolism. Front Biosci (Landmark Ed) (2014) 0.77
Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Rev (2014) 0.76
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.75
Bone Loss in HIV Infection. Curr Treat Options Infect Dis (2017) 0.75
CathepsinKCre mediated deletion of βcatenin results in dramatic loss of bone mass by targeting both osteoclasts and osteoblastic cells. Sci Rep (2016) 0.75
CLEC5A is critical for dengue virus-induced osteoclast activation and bone homeostasis. J Mol Med (Berl) (2016) 0.75
Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther (2017) 0.75
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Regulation of bone mass by Wnt signaling. J Clin Invest (2006) 5.59
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol (2000) 5.14
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 3.59
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med (2006) 3.40
Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med (2004) 2.94
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A (2005) 2.67
Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem (2002) 2.49
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest (2006) 2.11
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A (2005) 1.70
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
In vivo analysis of Wnt signaling in bone. Endocrinology (2007) 1.61
C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost (2008) 1.53
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS (2001) 1.50
Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res (2004) 1.45
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem (2008) 1.43
Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem (2003) 1.43
HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol (2005) 1.42
Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem (2002) 1.34
Eating bone or adding it: the Wnt pathway decides. Nat Med (2007) 1.30
Phosphorylation of 20S proteasome alpha subunit C8 (alpha7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by gamma-interferon. Biochem J (2004) 1.30
FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J Clin Invest (2005) 1.25
Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS (2001) 1.21
Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem (2002) 1.20
Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone (1995) 1.17
Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med (2004) 1.15
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med (2007) 1.15
Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr (1989) 1.14
How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem (1999) 1.07
Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol (2005) 1.04
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses (2007) 0.99
Adenomatous polyposis coli (APC), beta-catenin, and cadherin are expressed in human bone and cartilage. Histopathology (2001) 0.97
Colony-stimulating factor-1 increases osteoclast intracellular pH and promotes survival via the electroneutral Na/HCO3 cotransporter NBCn1. Endocrinology (2006) 0.97
Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J Cell Biochem (2004) 0.96
Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res (2002) 0.96
Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochem Biophys Res Commun (2006) 0.95
Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann N Y Acad Sci (2006) 0.95
Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone (2002) 0.94
Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS (2005) 0.90
IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res (2004) 0.88
Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. AIDS (2002) 0.81
Cadherin-6 mediates the heterotypic interactions between the hemopoietic osteoclast cell lineage and stromal cells in a murine model of osteoclast differentiation. J Cell Biol (1998) 0.80
The effects of arg-vasopressin on osteoblast-like cells in endothelial nitric oxide synthase-knockout mice and their wild type counterparts. Peptides (2005) 0.76
Modeling metabolic effects of the HIV protease inhibitor ritonavir in vitro. Am J Pathol (2007) 0.76
Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant (2005) 1.63
Surviving AIDS, and AIDS dementia. AIDS Read (2006) 1.39
Sustained release of microbicides by newly engineered vaginal rings. AIDS (2009) 1.38
A medical miracle, but for how long? AIDS Read (2005) 1.38
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol (2012) 1.33
Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology (2005) 1.27
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
A comparison of two approaches to text processing: facilitating chart reviews of radiology reports in electronic medical records. Perspect Health Inf Manag (2010) 1.14
The effects of Eculizumab on the pathology of malignant atrophic papulosis. Orphanet J Rare Dis (2013) 1.11
Potential roles for chemokine receptor CCR5 in the pathobiology of hepatitis C infection. Gastroenterology (2002) 1.08
Translating ideas into action: two new features initiated by Translational Research, as genomics enters the clinics. Transl Res (2011) 1.06
Accessibility and longevity of Internet citations in a clinical AIDS journal. AIDS Patient Care STDS (2005) 0.95
Genome-wide transcriptional profiling in human squamous cell carcinoma of the skin identifies unique tumor-associated signatures. J Dermatol (2006) 0.94
Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Am J Trop Med Hyg (2006) 0.94
The effect of antiretrovirals on vitamin D. Clin Infect Dis (2011) 0.91
Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J Immunol (2004) 0.90
Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem Biophys Res Commun (2011) 0.90
HIV and the lung in the HAART era. AIDS Read (2005) 0.89
Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol (2007) 0.88
Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol (2004) 0.88
Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma. Int J Cancer (2004) 0.86
Human sex hormone-binding globulin gene expression- multiple promoters and complex alternative splicing. BMC Mol Biol (2009) 0.84
Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol (2004) 0.83
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res (2013) 0.81
Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. J Immunol (2004) 0.81
Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies. J Neurol Sci (2009) 0.81
Making HIV testing routine. AIDS Read (2007) 0.81
Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood (2013) 0.80
The role of prisons in dissemination of HIV and hepatitis. AIDS Read (2005) 0.80
Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease. AIDS (2016) 0.79
Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model. Int J Cancer (2009) 0.79
A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City. Clin Infect Dis (2014) 0.79
Translating translational research. Transl Res (2006) 0.78
Impact of HAART on HIV-linked malignancies. AIDS Read (2003) 0.78
No more boring science, no more waste in clinical trials. Transl Res (2008) 0.78
Treating HIV infection with one pill per day. AIDS Patient Care STDS (2006) 0.77
Relationship of vitamin D, HIV, HIV treatment, and lipid levels in the Women's Interagency HIV Study of HIV-infected and uninfected women in the United States. J Int Assoc Provid AIDS Care (2014) 0.77
Drug resistance among HIV and its "friends". AIDS Read (2003) 0.77
Suppressing HIV transmission--through behavior and biology. AIDS Read (2006) 0.77
Hepatitis A and B virus immunization in HIV-infected persons. AIDS Read (2006) 0.77
Modeling metabolic effects of the HIV protease inhibitor ritonavir in vitro. Am J Pathol (2007) 0.76
The medical miracle: more questions. AIDS Read (2005) 0.75
Endothelial cell activation and apoptosis in the thrombotic microangiopathies. Br J Haematol (2004) 0.75
HCV infection in the setting of HIV: prevalence, disease, treatment. AIDS Read (2006) 0.75
Non-AIDS-defining malignancies and HAART. AIDS Read (2007) 0.75
The association of self-perception of body fat changes and quality of life in the Women's Interagency HIV Study. AIDS Care (2013) 0.75
Repetitive mucosal exposure to human herpesvirus-8 and protection against its penile-vaginal transmission. J Infect Dis (2003) 0.75
Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma. Cell Mol Immunol (2004) 0.75
HIV therapeutics in children and adults and their side effects. AIDS Read (2004) 0.75
Antiretroviral suppression of HIV in the context of persistently low CD4 counts: new insights. AIDS Read (2007) 0.75
Durability of clinical responses to anti-HIV therapies. AIDS Read (2008) 0.75
HIV therapy, guided by CD4 counts. AIDS Read (2006) 0.75
XV International AIDS Conference: science versus political science. AIDS Read (2004) 0.75
Treating primary HIV infection: HIV and the US sex-film industry. AIDS Read (2004) 0.75
Once-daily dosing and the treatment of HIV disease. AIDS Read (2006) 0.75
Antiretrovirals in the pipeline: anticipated updates. AIDS Read (2005) 0.75
Hot topics in AIDS therapeutics. AIDS Read (2002) 0.75
Learn a new trade: repairing broken pipelines. Transl Res (2008) 0.75
HPV-linked malignancy and the potential of vaccine-based prevention. AIDS Read (2005) 0.75
Pulse therapy. AIDS Read (2004) 0.75
Pivotal moments in HIV treatment: the 14th CROI. AIDS Read (2007) 0.75
HIV variants of low frequency may have a big impact. AIDS Read (2007) 0.75
Preventing sexually transmitted infections, 2008. AIDS Read (2008) 0.75
New trends in HIV disease worldwide. AIDS Read (2003) 0.75
Stem cell ping-pong: the politics of science. Transl Res (2010) 0.75
New information for some old editorials. AIDS Read (2004) 0.75
Recent studies of sexual transmission of HIV. AIDS Read (2006) 0.75
Mortality among patients with HIV infection in the HAART era. AIDS Read (2004) 0.75
Yet another World AIDS Day. AIDS Read (2006) 0.75
Recent highlights in clinical AIDS research. AIDS Read (2008) 0.75
Highlights of a year in AIDS. AIDS Read (2007) 0.75
Lessons from the 11th conference on retroviruses and opportunistic infections. AIDS Read (2004) 0.75
HAART, side effects, and viral transmission. AIDS Read (2004) 0.75
Seeking a cure for AIDS. AIDS Read (2008) 0.75
Leads from the Third International AIDS Society conference. AIDS Read (2005) 0.75
"Scientific gambles": AIDS microbicides and vaccines. AIDS Read (2002) 0.75
Debating global HIV incidence. AIDS Read (2006) 0.75
The "missing face" of AIDS. AIDS Read (2007) 0.75
Women and HIV. AIDS Read (2007) 0.75
Treating HIV infection without antiretrovirals; preventing HIV infection with them. AIDS Read (2004) 0.75
Bullet points: new topics in HIV/AIDS. AIDS Patient Care STDS (2002) 0.75
Biomedical methods for HIV prevention: new setbacks. AIDS Read (2008) 0.75
Stroke and anemia in HIV/AIDS. AIDS Read (2004) 0.75
Fighting a flexible virus with flexible drugs. AIDS Read (2004) 0.75
Bridging the gap between "ABC" and an AIDS vaccine. AIDS Read (2006) 0.75
Curb your enthusiasm. Transl Res (2007) 0.75
Start anti-HIV treatment early, in adults and infants. AIDS Read (2009) 0.75
Report from the National HIV Prevention Conference. AIDS Read (2005) 0.75
Newly identified human retrovirus receptor; new ways to prevent viral infections. AIDS Read (2004) 0.75
Compartmentalizing AIDS. AIDS Read (2008) 0.75
A cure for AIDS? AIDS Read (2007) 0.75
Know your epidemic. AIDS Read (2007) 0.75
HAART, hepatitis C, activated T cells, and mortality. AIDS Read (2003) 0.75
Mexico City: a call for "universal action now". AIDS Read (2008) 0.75
Update: a 25th anniversary and a UN global AIDS summit. AIDS Read (2006) 0.75
Two months of AIDS reports: critical lessons for HIV biology and medicine. AIDS Read (2008) 0.75
Treating HIV: when to start, who should treat, and still missing many. AIDS Read (2008) 0.75
Two areas in urgent need of HIV-related prevention: injection drug use and extensively drug-resistant TB. AIDS Read (2006) 0.75